Will Robust Exome and Genome Revenues Lift GeneDx's Q1 Earnings? [Yahoo! Finance]
Opko Health, Inc. (OPK)
Last opko health, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.opko.com
Company Research
Source: Yahoo! Finance
The renowned genetic testing company reported adjusted earnings per share (EPS) of 14 cents in the last reported quarter, topping the Zacks Consensus Estimate by 27.27%. GeneDx surpassed estimates in each of the trailing four quarters, the average surprise being 164.21%. Q1 Estimates for WGS The Zacks Consensus Estimate for GeneDx's first-quarter 2026 revenues is pegged at $110.5 million. This suggests a 26.9% rise from the year-ago reported figure. The Zacks Consensus Estimate for its first-quarter 2026 loss per share stands at 6 cents, compared to the year-ago quarter's EPS of 28 cents. Estimate Revision Trend Ahead of GeneDx's Q1 Earnings Estimates for GeneDx's first-quarter loss have remained constant at 6 cents per share in the past 60 days. Here's a brief overview of the company's progress ahead of this announcement. Factors at Play Building on a strong finish to 2025, GeneDx is likely to have extended the exome and genome momentum in the first quarter. The comp
Show less
Read more
Impact Snapshot
Event Time:
OPK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPK alerts
High impacting Opko Health, Inc. news events
Weekly update
A roundup of the hottest topics
OPK
News
- OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell LymphomasGlobeNewswire
- OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026GlobeNewswire
- GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026 [Yahoo! Finance]Yahoo! Finance
- OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19GlobeNewswire
- Craig-Hallum Reaffirms Buy on GeneDx (WGS) With $153 Price Target [Yahoo! Finance]Yahoo! Finance
OPK
Earnings
- 2/26/26 - Beat
OPK
Analyst Actions
- 3/2/26 - Barrington Research
OPK
Sec Filings
- 3/20/26 - Form 4
- 3/20/26 - Form 4
- 3/20/26 - Form 3
- OPK's page on the SEC website